Title:Bioinformatics Analysis Reveals Centromere Protein K Can Serve as Potential Prognostic Biomarker and Therapeutic Target for Non-small Cell Lung Cancer
Volume: 16
Issue: 1
Author(s): Yimin Luo, Xihua Wang, Li Li, Qun Wang, Yue Hu, Can He and Mei Zhang*
Affiliation:
- Department of Respiratory Medicine, Zhongda Hospital Affiliated to Southeast University, School of Medicine, Southeast University, Nanjing,China
Keywords:
Non-small cell lung cancer, CENPK, prognosis, therapeutic target, biomarker, lymphocytes.
Abstract:
Background: Non-small cell lung carcinoma (NSCLC) accounts for 80% of all lung
cancer cases, which have been a leading cause of morbidity and mortality worldwide. Previous
studies demonstrated that centromere proteins were dysregulated and involved in regulating the
tumorigenesis and development of human cancers. However, the roles of centromere protein
family members in NSCLC remained to be further elucidated.
Objective: The present study aimed to explore the roles of centromere protein family members in
NSCLC.
Methods: GEPIA (http://gepia.cancer-pku.cn/) was used to analyze the target’s expression
between normal and human cancers. We explored the prognostic value of centromere proteins in
NSCLC using the Kaplan–Meier plotter (http://kmplot.com). The protein-protein interaction
among centromere proteins was determined using GeneMANIA (http://www.genemania.org).
TISIDB (http://cis.hku.hk/TISIDB) database was used to detect the relationship between
centromere protein expression and clinical stages, lymphocytes, immunomodulators and
chemokines in NSCLC. The DAVID database (https://david.ncifcrf.gov) was used to detect
potential roles of CENPK using its co-expressing genes.
Results: The present study for the first time showed that centromere protein family members
including CENPA, CENPF, CENPH, CENPI, CENPK, CENPM, CENPN, CENPO, CENPQ,
CENPU were dysregulated and correlated to the poor prognosis of patients with LUAD. CENPK
showed the greatest correlation with the prognosis of patients with NSCLC. We found that
CENPK was significantly highly expressed in LUAD samples and overexpression of CENPK was
remarkably correlated to the shorter OS and DFS in patients with a different stage of NSCLC. Of
note, this study for the first time showed that CENPK was significantly correlated to the
lymphocytes and immunomodulators using the TISIDB database.
Conclusion: In summary, CENPK can serve as a novel biomarker for the diagnosis of patients
with NSCLC.
